Hot Investor Mandate 3: Global VC Firm Invests in Infectious Disease, Inflammation and Rare Diseases

15 Dec

A venture capital firm specializing in early stage investments in the technology and life sciences sectors has offices in Europe, the US and Australia. In Life Sciences, the firm typically invests at seed stage or before a company has been formed and develop these early opportunities through preclinical phase; at late preclinical/early clinical stage the firm gets co-investors involved. The firm prefers areas where there are multiple capital efficient routes to market, with opportunities for early proof of concept or early outlicensing or exits.

The firm manages a $150M fund and makes investments from $100K to $10M, depending on the opportunity. The firm is seeking a couple of opportunities to add to its portfolio. The firm invests in companies based in the USA and/or Europe.

The firm looks at early stage biotech therapeutics. In terms of indications, the firm is interested in anti-infectives and particularly antimicrobial resistance, as well as immuno-modulatory anti-inflammatory indications and orphan and rare diseases.

The firm looks for a strong management team with track record and a ground-breaking technology addressing an unmet need. The firm seeks to take significant minority stakes and board seats. In addition, the firm will provide hands-on support from its own bench of senior execs, experts and advisors to accelerate its ventures after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: